Stockreport

bluebird bio to Present New Data from Clinical Studies of LentiGlobin™ Gene Therapy for Transfusion-Dependent ß-thalassemia (TDT) and LentiGlobin Gene Therapy for Sickle Cell Disease (SCD)...

bluebird bio, Inc.  (BLUE) 
Last bluebird bio, inc. earnings: 2/18 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.bluebirdbio.com/investor-overview
PDF Additional follow-up from the completed Phase 1/2 Northstar (HGB-204) study of LentiGlobin in adolescents and adults with TDT New data from ongoi [Read more]